BG Medicine (OTCMKTS:BGMD – Get Rating) and Lucira Health (NASDAQ:LHDX – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Insider & Institutional Ownership

57.0% of Lucira Health shares are held by institutional investors. 6.5% of BG Medicine shares are held by company insiders. Comparatively, 30.4% of Lucira Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BG Medicine and Lucira Health's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BG Medicine and Lucira Health, as reported by MarketBeat.

Risk and Volatility

BG Medicine has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Lucira Health has a beta of 3.75, suggesting that its share price is 275% more volatile than the S&P 500.

Earnings & Valuation

This table compares BG Medicine and Lucira Health's revenue, earnings per share and valuation.

BG Medicine has higher earnings, but lower revenue than Lucira Health.

Summary

Lucira Health beats BG Medicine on 5 of the 8 factors compared between the two stocks.

About BG Medicine

(Get Rating)

BG Medicine, Inc. is a life sciences company. It engages in developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The firm distributes products such as BGM Galectin-3 to clinical laboratories, hospitals, and healthcare providers. The company was founded in February 2000 by Jan van der Greef and is headquartered in Foxboro, MA.

About Lucira Health

(Get Rating)

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Receive News & Ratings for BG Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine and related companies with MarketBeat.com's FREE daily email newsletter.